Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 8, 2007

Ablynx and Boehringer Ingelheim Embark on $265M Alzeimer’s Collaboration

  • Boehringer Ingelheim and Ablynx inked a deal worth almost $265 million to discover and develop new therapies for Alzheimer’s disease. The worldwide collaboration and license agreement will use Ablynx’ Nanobodies®, a novel class of therapeutic proteins.

    In addition Boehringer Ingelheim will commence a joint research program with Ablynx scientists. Boehringer Ingelheim will be solely responsible for the development, manufacture, and commercialization of any products resulting from the collaboration. The deal includes an upfront fee, development and commercial milestones., and sales-based royalties.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »